207 related articles for article (PubMed ID: 23409060)
41. Facile synthesis and
Walker D; Li Y; Roxin Á; Schaffer P; Adam MJ; Perrin DM
Bioorg Med Chem Lett; 2016 Oct; 26(20):5126-5131. PubMed ID: 27623550
[TBL] [Abstract][Full Text] [Related]
42. Comparison of Immuno-PET of CD138 and PET imaging with
Bailly C; Gouard S; Lacombe M; Remaud-Le Saëc P; Chalopin B; Bourgeois M; Chouin N; Tripier R; Halime Z; Haddad F; Faivre-Chauvet A; Kraeber-Bodéré F; Chérel M; Bodet-Milin C
Oncotarget; 2018 Feb; 9(10):9061-9072. PubMed ID: 29507674
[TBL] [Abstract][Full Text] [Related]
43. Monitoring CD8a
Kristensen LK; Christensen C; Alfsen MZ; Cold S; Nielsen CH; Kjaer A
Mol Imaging Biol; 2020 Aug; 22(4):1021-1030. PubMed ID: 32086762
[TBL] [Abstract][Full Text] [Related]
44. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.
Lapa C; Knop S; Schreder M; Rudelius M; Knott M; Jörg G; Samnick S; Herrmann K; Buck AK; Einsele H; Lückerath K
Theranostics; 2016; 6(2):254-61. PubMed ID: 26877783
[TBL] [Abstract][Full Text] [Related]
45. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
46. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
[TBL] [Abstract][Full Text] [Related]
47. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma.
Haznedar R; Akı SZ; Akdemir OU; Ozkurt ZN; Ceneli O; Yağcı M; Sucak GT; Unlü M
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1046-53. PubMed ID: 21287167
[TBL] [Abstract][Full Text] [Related]
48. Targeting CAIX with [
Yang X; Zhu H; Yang X; Li N; Huang H; Liu T; Guo X; Xu X; Xia L; Deng C; Tian X; Yang Z
Mol Pharm; 2019 Apr; 16(4):1532-1540. PubMed ID: 30803240
[TBL] [Abstract][Full Text] [Related]
49. New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative.
Halime Z; Frindel M; Camus N; Orain PY; Lacombe M; Bernardeau K; Chérel M; Gestin JF; Faivre-Chauvet A; Tripier R
Org Biomol Chem; 2015 Dec; 13(46):11302-14. PubMed ID: 26419637
[TBL] [Abstract][Full Text] [Related]
50. Targeted imaging of very late antigen-4 for noninvasive assessment of lung inflammation-fibrosis axis.
Zhu Q; Barnes CE; Mannes PZ; Latoche JD; Day KE; Nedrow JR; Novelli EM; Anderson CJ; Tavakoli S
EJNMMI Res; 2023 Jun; 13(1):55. PubMed ID: 37273103
[TBL] [Abstract][Full Text] [Related]
51. Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.
Dankerl A; Liebisch P; Glatting G; Friesen C; Blumstein NM; Kocot D; Wendl C; Bunjes D; Reske SN
Radiology; 2007 Feb; 242(2):498-508. PubMed ID: 17179397
[TBL] [Abstract][Full Text] [Related]
52. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
[TBL] [Abstract][Full Text] [Related]
53. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and Preclinical Evaluation of a
Li H; Yuan L; Long Y; Fang H; Li M; Liu Q; Xia X; Qin C; Zhang Y; Lan X; Gai Y
Mol Pharm; 2020 Aug; 17(8):3000-3008. PubMed ID: 32544337
[TBL] [Abstract][Full Text] [Related]
56. Exploring pitfalls of
Striese F; Sihver W; Gao F; Bergmann R; Walther M; Pietzsch J; Steinbach J; Pietzsch HJ
Amino Acids; 2018 Oct; 50(10):1415-1431. PubMed ID: 30039310
[TBL] [Abstract][Full Text] [Related]
57. (64)Cu-labeled peptide for PET of breast carcinomas expressing the Thomsen-Friedenreich carbohydrate antigen.
Kumar SR; Gallazzi FA; Quinn TP; Deutscher SL
J Nucl Med; 2011 Nov; 52(11):1819-26. PubMed ID: 21984800
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and comparative evaluation of novel (64)Cu-labeled high affinity cell-specific peptides for positron emission tomography imaging of tumor vasculature.
Merrill JR; Krajewski K; Yuan H; Frank JE; Lalush DS; Patterson C; Veleva AN
Biomaterials; 2016 Apr; 84():241-249. PubMed ID: 26839954
[TBL] [Abstract][Full Text] [Related]
59. Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.
Caserta E; Chea J; Minnix M; Poku EK; Viola D; Vonderfecht S; Yazaki P; Crow D; Khalife J; Sanchez JF; Palmer JM; Hui S; Carlesso N; Keats J; Kim Y; Buettner R; Marcucci G; Rosen S; Shively J; Colcher D; Krishnan A; Pichiorri F
Blood; 2018 Feb; 131(7):741-745. PubMed ID: 29301755
[TBL] [Abstract][Full Text] [Related]
60. In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [
Ghai A; Fettig N; Fontana F; DiPersio J; Rettig M; Neal JO; Achilefu S; Shoghi KI; Shokeen M
EJNMMI Res; 2021 Sep; 11(1):97. PubMed ID: 34586539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
